Division of Rheumatology, Department of Medicine, UMDNJ/RWJMS , MEB 468, PO Box 19, New Brunswick, NJ 08903-0019, USA.
Expert Opin Biol Ther. 2012 Sep;12(9):1265-75. doi: 10.1517/14712598.2012.705825. Epub 2012 Jul 12.
Gout is a painful inflammatory arthritis with a prevalence of approximately 4% in the United States, affecting an estimated 8.3 million adults. The past 20 years have shown significant increases in the number of patients with gout and its incidence may still be increasing. Current treatment options to control the pain and inflammation of acute gout include nonsteroidal anti-inflammatory drugs, colchicine and corticosteroids, although patients are often unresponsive to, intolerant of, or have contraindications for, these therapies. Additional treatment options are therefore needed for this population with difficult-to-treat gout.
Currently available and investigational anti-inflammatory agents for acute and chronic gout will briefly be reviewed. Canakinumab , a fully human monoclonal anti-interleukin (IL)-1β antibody that selectively blocks IL-1β and that is being investigated for the treatment of gout, will be discussed in greater detail.
Canakinumab has been found to be superior to triamcinolone acetonide in acute gout and to colchicine in gout attack prophylaxis in reducing pain and risk of new gout attacks. Canakinumab's long half-life contributes to its prolonged anti-inflammatory effects.
痛风是一种疼痛性炎症性关节炎，在美国的患病率约为 4%，估计有 830 万成年人受其影响。过去 20 年显示出痛风患者数量的显著增加，其发病率可能仍在上升。目前控制急性痛风疼痛和炎症的治疗选择包括非甾体抗炎药、秋水仙碱和皮质类固醇，但患者通常对这些治疗无反应、不耐受或存在禁忌。因此，对于这种难治性痛风患者，需要额外的治疗选择。
简要回顾了目前用于急性和慢性痛风的抗炎药物。将详细讨论一种新型的、正在研究中的抗白细胞介素（IL）-1β单克隆抗体卡那单抗，它可选择性阻断 IL-1β，被研究用于治疗痛风。
卡那单抗在急性痛风中优于曲安奈德，在痛风发作预防中优于秋水仙碱，可降低疼痛和新发痛风发作的风险。卡那单抗的长半衰期使其抗炎作用持久。
